INFO & CONTACTS:  +39 02 2390 1

A Phase 2 Open-label Randomized Study of V940 in Combination With BCG Versus BCG Monotherapy in Participants With High-risk Non-muscle Invasive Bladder Cancer (INTerpath-011)

Phase: Phase I-II clinical trials

Principal Investigator: Dott. Procopio Giuseppe

Main Facility: Oncologia Medica Genitourinaria

Drug: V940 e BCG

Pathologies: Urological cancers (kidney, bladder, urinary tract, others)

Each participant will participate in the study for approximately 5 years from the time the participant provides documented informed consent through the final protocol-specified contact. After a screening period of up to 56 days each, each participant will be receiving assigned study intervention for approximately 1.5 years. After the end of treatment (assuming completion of 1.5 years of treatment), each participant will be followed for approximately 3.5 years such that the total duration of treatment and follow-up is approximately 5 years. After screening, each participant will be assigned to receive study intervention until one of the conditions for discontinuation of study intervention is met. After the end of treatment, each participant will be followed for the occurrence of AEs, SAEs, and other reportable safety events. All participants will be followed for disease status, bladder status, and survival status until withdrawal of consent, becoming lost to follow-up, death, or the end of the study, or for a maximum of 5 years from the time of randomization (Cohort A)/first dose (Cohort B), whichever occurs first. 

Last update: 20/04/2026

Subscribe to the newsletter

Sign up for our newsletter to stay informed about news, events, and updates from the Institute

Subscribe